JOHNSON & JOHNSON

JNJ
Pharmaceutical preparations
Last filing · Quarter 3 · Sep 27, 2026
Financial Statements Ratios
Export XLSX
Statement
Income StatementBalance SheetCash Flow
Period
Annual Quarterly
Order

41 more quarters with Pro

JOHNSON & JOHNSON back to 2009, every line as filed.

Create a free account
USD ($)
$ in Millions, shares in Millions		Sep 27, 2026Jun 28, 2026Mar 29, 2026Sep 28, 2025Jun 29, 2025Mar 30, 2025Sep 29, 2024Jun 30, 2024Mar 31, 2024Oct 1, 2023Jul 2, 2023Apr 2, 2023Oct 2, 2022Jul 3, 2022Apr 3, 2022Oct 3, 2021Jul 4, 2021Apr 4, 2021Sep 27, 2020Jun 28, 2020Mar 29, 2020Sep 29, 2019Jun 30, 2019Mar 31, 2019Sep 30, 2018Jul 1, 2018Apr 1, 2018Oct 1, 2017Jul 2, 2017Apr 2, 2017Oct 2, 2016Jul 3, 2016Apr 3, 2016Sep 27, 2015Jun 28, 2015Mar 29, 2015Sep 28, 2014Jun 29, 2014Mar 30, 2014Sep 29, 2013Jun 30, 2013Mar 31, 2013Sep 30, 2012Jul 1, 2012Apr 1, 2012Oct 2, 2011Jul 3, 2011Apr 3, 2011Oct 3, 2010Jul 4, 2010Apr 4, 2010Sep 27, 2009Jun 28, 2009
Sales to customers (Note 9)
$ 25,399
$ 25,310
$ 24,062
$ 23,993
$ 23,743
$ 21,893
$ 22,471
$ 22,447
$ 21,383
$ 21,351
$ 25,530
$ 24,746
Sales to customers (Note 9)
-
-
-
-
-
-
-
-
-
-
-
-
Sales to customers percent to sales
1
1
1
1
1
1
1
1
1
1
1
1
Cost of products sold
8,097
8,051
8,106
7,303
7,628
7,357
6,963
6,869
6,511
6,606
8,212
8,395
Cost of products sold percent to sales
0.32
0.32
0.34
0.3
0.32
0.34
0.31
0.31
0.3
0.31
0.32
0.34
Gross profit
17,302
17,259
15,956
16,690
16,115
14,536
15,508
15,578
14,872
14,745
17,318
16,351
Gross Profit Percent To Sales
0.68
0.68
0.66
0.7
0.68
0.66
0.69
0.69
0.7
0.69
0.68
0.66
Selling, marketing and administrative expenses
6,285
6,432
6,034
5,922
5,889
5,112
5,478
5,681
5,257
5,400
6,665
6,138
Selling marketing and administrative expenses percent to sales
0.25
0.25
0.25
0.25
0.25
0.23
0.24
0.25
0.25
0.25
0.26
0.25
Research and development expense
4,652
3,653
3,527
3,672
3,516
3,225
4,952
3,440
3,542
3,447
3,829
3,563
Research and development expense percent to sales
0.18
0.14
0.15
0.15
0.15
0.15
0.22
0.15
0.17
0.16
0.15
0.14
In-process research and development impairments
339
-
36
-
0
-
0
194
0
206
-
-
In-process research and development
-
-
-
-
-
-
-
-
-
-
-
49
In-process research and development percent to sales
0.01
-
0
-
0
-
0
0.01
0
0.01
-
0
Interest income
(186)
(219)
(229)
(227)
(260)
(332)
(292)
(395)
(364)
(374)
(369)
(235)
Interest income percent to sales
(0.01)
(0.01)
(0.01)
(0.01)
(0.01)
(0.01)
(0.01)
(0.02)
(0.02)
(0.02)
(0.01)
(0.01)
Interest expense, net of portion capitalized
217
281
272
245
308
204
193
270
155
192
346
215
Interest expense, net of portion capitalized percent to sales
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
Other (income) expense, net
5,780
331
294
(478)
107
(7,321)
1,798
653
2,404
499
(60)
7,228
Other (income) expense, net percent to sales
0.23
0.01
0.01
(0.02)
0.01
(0.33)
0.08
0.03
0.11
0.02
0
0.29
Restructuring (Note 12)
181
34
32
63
64
17
41
(13)
164
158
145
130
Restructuring charge percent to sales
0.01
0
0
0
0
0
0
0
0.01
0.01
0.01
0.01
Earnings before provision for taxes on income
34
6,747
5,990
7,493
6,491
13,631
3,338
5,748
3,714
5,217
6,762
(737)
Restructuring expense Percent to Sales
-
-
-
-
-
-
-
-
-
-
-
-
Earnings before provision for taxes on income percent to sales
0
0.27
0.25
0.31
0.27
0.62
0.15
0.26
0.17
0.24
0.27
(0.03)
(Benefit from)/Provision for taxes on income (Note 5)
(176)
1,213
755
2,341
954
2,632
644
1,062
459
908
1,618
(669)
Provision for taxes on income percent to sales
(0.01)
0.05
0.03
0.1
0.04
0.12
0.03
0.05
0.02
0.04
0.06
(0.03)
Net earnings from continuing operations
-
-
-
-
-
-
2,694
4,686
3,255
4,309
-
-
Net earnings from continuing operations percent of sales
0.01
0.22
0.22
0.21
0.23
0.5
0.12
0.21
0.15
0.2
-
-
Net earnings from discontinued operations, net of tax (Note 13)
-
-
-
-
-
-
0
0
0
21,719
-
-
NET EARNINGS
-
-
-
-
-
-
-
-
-
-
-
-
Net Earnings percent to sales
-
-
-
-
-
-
-
-
-
-
-
-
Add: Net loss attributable to noncontrolling interest, net of tax
-
-
-
-
-
-
-
-
-
-
-
-
Net loss attributable to noncontrolling interest percent to sales
-
-
-
-
-
-
-
-
-
-
-
-
Net earnings
$ 210
$ 5,534
$ 5,235
$ 5,152
$ 5,537
$ 10,999
$ 2,694
$ 4,686
$ 3,255
$ 26,028
$ 5,144
$ (68)
Net earnings percent to sales
-
-
-
-
-
-
-
-
-
-
0.2
0
NET EARNINGS PER SHARE
                                                     
Continuing operations - basic (in dollars per share)
-
-
-
-
-
-
$ 1.12
$ 1.95
$ 1.35
$ 1.71
-
-
Discontinued operations - basic (in dollars per share)
-
-
-
-
-
-
0.00
0.00
0.00
8.61
-
-
Total net earnings per share - basic (in dollars per share)
0.09
2.30
2.17
2.14
2.30
4.57
1.12
1.95
1.35
10.32
1.98
(0.03)
Continuing operations - diluted (in dollars per share)
-
-
-
-
-
-
1.11
1.93
1.34
1.69
-
-
Discontinued operations - diluted (in dollars per share)
-
-
-
-
-
-
0.00
0.00
0.00
8.52
-
-
Total net earnings per share - diluted (in dollars per share)
0.09
2.27
2.14
2.12
2.29
4.54
1.11
1.93
1.34
10.21
1.96
(0.03)
CASH DIVIDENDS PER SHARE
-
-
-
-
-
-
-
-
-
-
-
-
Avg. shares outstanding
                                                     
AVERAGE SHARES OUTSTANDING
                                                     
Basic (shares)
2,409.6
2,407.4
2,408.7
2,408.3
2,406.3
2,407.2
2,407.2
2,406.8
2,408.2
2,522.9
2,598.4
2,605.5
Diluted (shares)
2,448.6
2,440.1
2,445.2
2,428.6
2,419.1
2,423.8
2,427.9
2,422.0
2,430.1
2,549.7
2,625.7
2,605.5
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
-
-
-
-
-
-
-
-
-
-
-
-